Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

PubMed  Google Scholar 

Xie S, Wu Z. The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges. Biomed Pharmacother. 2021;138:111450.

Article  CAS  PubMed  Google Scholar 

Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563–79.

Article  PubMed  PubMed Central  Google Scholar 

Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.

Article  CAS  PubMed  Google Scholar 

Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.

Article  CAS  PubMed  Google Scholar 

Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.

Article  CAS  PubMed  Google Scholar 

Jakobsen KR, Demuth C. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 2016;5(2):172–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stewart EL, Tan SZ. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. 2015;4(1):67–81.

CAS  PubMed  PubMed Central  Google Scholar 

Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(7):624–36.

Article  CAS  PubMed  Google Scholar 

Fang W, Zhao Y, Luo Y, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024;332(7):561–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Hu Q, Zhang X, et al. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition. Oncol Rep. 2018;39(4):1783–92.

CAS  PubMed  Google Scholar 

Spengler G, Takács D, Horváth A, et al. Multidrug resistance reversing activity of newly developed phenothiazines on P-glycoprotein (ABCB1)-related resistance of mouse T-lymphoma cells. Anticancer Res. 2014;34(4):1737–41.

CAS  PubMed  Google Scholar 

Shah D, Ajazuddin, Bhattacharya S. Role of natural P-gp inhibitor in the effective delivery for chemotherapeutic agents. J Cancer Res Clin Oncol. 2023;149(1):367–91.

Article  CAS  PubMed  Google Scholar 

Dickerson H, Diab A. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects. Int J Mol Sci. 2024;25:18.

Article  Google Scholar 

Yin W, Xiang D, Wang T, et al. The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells. Sci Rep. 2021;11(1):10791.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Creemers SG, van Koetsveld PM, De Herder WW, et al. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. Endocr Relat Cancer. 2019;26(3):367–78.

Article  CAS  PubMed  Google Scholar 

Traber GM, Yu AM. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. J Pharmacol Exp Ther. 2023;384(1):133–54.

Article  CAS  PubMed  Google Scholar 

Zhang H, Xu H. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev. 2021;41(1):525–55.

Article  CAS  PubMed  Google Scholar 

Wallen M, Aqil F. Milk/colostrum exosomes: A nanoplatform advancing delivery of cancer therapeutics. Cancer Lett. 2023;561:216141.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Z, Wang L, Tu L, et al. Folic Acid-Modified Milk Exosomes Delivering c-Kit siRNA Overcome EGFR-TKIs Resistance in Lung Cancer by Suppressing mTOR Signaling and Stemness. Int J Biol Sci. 2025;21(1):382–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng Z, Li Z. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J Control Release. 2019;311–312:43–9.

Article  PubMed  PubMed Central  Google Scholar 

Barok M, Puhka M. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer. 2018;18(1):504.

Article  PubMed  PubMed Central  Google Scholar 

Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498–503.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Limoni SK, Moghadam MF. Engineered Exosomes for Targeted Transfer of siRNA to HER2 Positive Breast Cancer Cells. Appl Biochem Biotechnol. 2019;187(1):352–64.

Article  CAS  PubMed  Google Scholar 

Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;4:3.

Google Scholar 

González-Sarrías A, Iglesias-Aguirre CE, Cortés-Martín A, et al. Milk-Derived Exosomes as Nanocarriers to Deliver Curcumin and Resveratrol in Breast Tissue and Enhance Their Anticancer Activity. Int J Mol Sci. 2022;23(5):2860.

Article  PubMed  PubMed Central  Google Scholar 

Pullan J, Dailey K, Bhallamudi S, et al. Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells. ACS Appl Bio Mater. 2022;5(5):2163–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li D, Gong L, Lin H, et al. Hyaluronic Acid-Coated Bovine Milk Exosomes for Achieving Tumor-Specific Intracellular Delivery of miRNA-204. Cells. 2022;11(19):3065.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H, Sun Y, Wang J, et al. Hyaluronic acid-modified milk exosomes carrying ZNF516 inhibit ABCC5 and contribute to pemetrexed sensitivity in lung adenocarcinoma. Hum Cell. 2025;38(3):92.

Article  PubMed  Google Scholar 

Zhang A, Huang J, Liu Y, et al. Hyaluronic acid application strategies for plant bioactive component delivery: A review. Int J Biol Macromol. 2024;282(Pt 3):137129.

Article  CAS  PubMed  Google Scholar 

Del Pozo-Acebo L, Hazas MLL, Tomé-Carneiro J, et al. Bovine Milk-Derived Exosomes as a Drug Delivery Vehicle for miRNA-Based Therapy. Int J Mol Sci. 2021;22(3):1105.

Article  PubMed  PubMed Central  Google Scholar 

Reita D, Pabst L, Pencreach E, et al. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. Cancers (Basel). 2021;13(19):4926.

Article